Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

1477results about "Boron compound active ingredients" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Combinations and modes of administration of therapeutic agents and combination therapy

ActiveUS20060263434A1Heavy metal active ingredientsBiocideNanoparticleSurgery procedure

The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.

Combinations and modes of administration of therapeutic agents and combination therapy

Combinations and modes of administration of therapeutic agents and combination therapy

Combinations and modes of administration of therapeutic agents and combination therapy

Owner:ABRAXIS BIOSCI LLC

Boron-containing small molecules

ActiveUS20060234981A1Growth inhibitionAvoid infectionAntibacterial agentsBiocideFungal microorganismsTopical treatment

This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and / or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

Boron-containing small molecules

Boron-containing small molecules

Boron-containing small molecules

Owner:ANACOR PHARMA INC

Boron-containing small molecules

ActiveUS20070155699A1BiocideAntimycoticsFungal microorganismsTopical treatment

This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and / or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

Boron-containing small molecules

Boron-containing small molecules

Boron-containing small molecules

Owner:ANACOR PHARMA LLC

Methods for the identification, assessment, and treatment of patients with cancer therapy

ActiveUS20060281122A1Reduced growth rateEliminate ineffective or inappropriate therapeutic agentsMechanical/radiation/invasive therapiesMicrobiological testing/measurementAbnormal tissue growthRegimen

The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

Methods for the identification, assessment, and treatment of patients with cancer therapy

Methods for the identification, assessment, and treatment of patients with cancer therapy

Owner:MILLENNIUM PHARMA INC

Boron-containing small molecules

ActiveUS20090227541A1Antibacterial agentsBiocideBoron containingStereochemistry

This invention provides, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

Boron-containing small molecules

Boron-containing small molecules

Boron-containing small molecules

Owner:ANACOR PHARMA INC

Boron-Containing Small Molecules as Anti-Inflammatory Agents

ActiveUS20090291917A1BiocideSenses disorderMedicineBoron containing

Compounds and methods of treating anti-inflammatory conditions are disclosed.

Boron-Containing Small Molecules as Anti-Inflammatory Agents

Boron-Containing Small Molecules as Anti-Inflammatory Agents

Boron-Containing Small Molecules as Anti-Inflammatory Agents

Owner:ANACOR PHARMA INC

Compounds for the Treatment of Periodontal Disease

InactiveUS20070286822A1Cosmetic preparationsBiocideMedicineCompound (substance)

Compounds, compositions and methods are provided which are useful in the treatment of periodontal disease.

Compounds for the Treatment of Periodontal Disease

Compounds for the Treatment of Periodontal Disease

Compounds for the Treatment of Periodontal Disease

Owner:ANACOR PHARMA INC

Boron-containing small molecules

ActiveUS7582621B2Antibacterial agentsBiocideTopical treatmentFungal nail infection

This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and / or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

Boron-containing small molecules

Boron-containing small molecules

Boron-containing small molecules

Owner:ANACOR PHARMA INC

Formulation of boronic acid compounds

InactiveUS6958319B2Facilitated releaseBiocidePowder deliveryCombinatorial chemistryBoric acid

The present invention provides stable compounds prepared from boronic acid and lyophilized compounds thereof of the formula (1):

in which Z¹and Z²are moieties derived from sugar. The invention also provides methods for preparing such compounds. Lyophilizing a mixture comprising a boronic acid compound and a moiety derived from sugar produces a stable composition that readily releases the boronic acid compound upon reconstitution in aqueous media.

Formulation of boronic acid compounds

Formulation of boronic acid compounds

Formulation of boronic acid compounds

Owner:US DEPT OF HEALTH & HUMAN SERVICES

Treatment of protein degradation disorders

ActiveUS20060239909A1Augmenting protein stressReduce sensitivityCompounds screening/testingBiocideProteasome degradationCompound (substance)

The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC / TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.

Treatment of protein degradation disorders

Treatment of protein degradation disorders

Treatment of protein degradation disorders

Owner:DANA FARBER CANCER INST INC +1

Composition for promoting healthy bone structure

InactiveUS6447809B1Increase bone densityPrevents radial bone lossBiocideHeavy metal active ingredientsVitamin CRegimen

A dietary supplement for benefitting human bone health includes a calcium source, a source of vitamin D activity, and an osteoblast stimulant. A preferred calcium source is microcrystalline hydroxyapatite, which also contains protein (mostly collagen), phosphorus, fat, and other minerals. A preferred source of vitamin D activity is cholecalciferol, and a preferred osteoblast stimulant is ipriflavone. In addition to these basic ingredients, the composition can further include various other minerals known to occur in bone, vitamin C, and glucosamine sulfate, all of which exert beneficial effects on growth and maintenance of healthy bone. A method for benefitting human bone health involves administering a daily regimen of the dietary supplement.

Owner:PHOENIX DICHTUNGSTECHN +1

Aryl and heteroaryl compounds, compositions and methods of use

InactiveUS20050049310A1Reduce hypoxiaInduce red blood cell productionBiocideOrganic chemistryArylErythropoietin receptor

This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such compositions. The compounds of Formula (I) may activate an erythropoietin receptor and thus, may be useful to induce red blood cell production. The compounds of Formula (I) and compositions including compounds of Formula (I) may be useful in a variety of applications including the management, treatment and/or control of diseases caused at least in part by deficient (or inefficient) EPO production relative to hemoglobin level.

Aryl and heteroaryl compounds, compositions and methods of use

Aryl and heteroaryl compounds, compositions and methods of use

Aryl and heteroaryl compounds, compositions and methods of use

Owner:VTV THERAPEUTICS LLC

Combination treatment of cd38-expressing tumors

ActiveUS20100092489A1Good curative effectImprove survivalBoron compound active ingredientsSkeletal disorderAntiendomysial antibodiesOncology

The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non- corticosteroid chemotherapeutic agent.

Combination treatment of cd38-expressing tumors

Combination treatment of cd38-expressing tumors

Combination treatment of cd38-expressing tumors

Owner:GENMAB AS

Method of regulating glucose metabolism, and reagents related thereto

InactiveUS20030153509A1Reduce insulin resistanceExcellent hostBiocideDipeptide ingredientsAcute hyperglycaemiaChylomicron

The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.

Method of regulating glucose metabolism, and reagents related thereto

Method of regulating glucose metabolism, and reagents related thereto

Method of regulating glucose metabolism, and reagents related thereto

Owner:1149336 ONTARIO +2

Boron-containing small molecules

InactiveUS20100256092A1Prevent bacterial growthInhibiting β-lactamaseAntibacterial agentsBiocideBoron containingSmall molecule

This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.

Boron-containing small molecules

Boron-containing small molecules

Boron-containing small molecules

Owner:ANACOR PHARMA INC +1

Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)

InactiveUS20060046978A1BiocideOrganic chemistryAngiotensin-converting enzymeDipeptidyl peptidase

This invention relates to novel compounds, compositions containing the compounds, that inhibit dipeptidyl peptidase (especially DPP-IV) and neprilysin (NEP, neutral endopeptidase) as well as dipeptidyl peptidase (especially DPP-IV) and angiotensin converting enzyme (ACE) and/or dipeptidyl Peptidase (especially DPP-IV) and vasopeptidases (especially ACE and NEP). These compounds and pharmaceutical compositions thereof are useful for the treatment as well as the prevention of type 2 diabetes mellitus.

Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)

Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)

Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)

Owner:MORPHOCHEM AG

Beta-lactamase inhibitors

InactiveUS20140194386A1Modulate activityUseful in treatmentAntibacterial agentsBiocideOrganic chemistryBeta-Lactamase Inhibitors

Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

Beta-lactamase inhibitors

Beta-lactamase inhibitors

Beta-lactamase inhibitors

Owner:VENATORX PHARMA INC

Boron-containing small molecules

ActiveUS7816344B2Antibacterial agentsBiocideOxygenBoron

This invention provides, among other things, novel oxaboroles which are monosubstituted at the 3-, 6-, or 7-position, or disubstituted at the 3- / 6- or 3- / 7- positions, which are useful for treating bacterial infections, pharmaceutical compositions containing such oxaboroles, as well as combinations of these oxaboroles with at least one additional therapeutically effective agent.

Boron-containing small molecules

Boron-containing small molecules

Boron-containing small molecules

Owner:ANACOR PHARMACEUTICALS LLC

Anti-tumor agents

InactiveUS6890904B1Prevent proliferationMinimize potentialDipeptide ingredientsTetrapeptide ingredientsAbnormal tissue growthLymphatic Spread

A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.

Anti-tumor agents

Anti-tumor agents

Anti-tumor agents

Owner:DARA BIOSCI

Beta-lactamase inhibitors

InactiveUS20100292185A1Reduce bacterial resistanceAntibacterial agentsSilicon organic compoundsStereochemistryBeta-Lactamase Inhibitors

Disclosed herein are α-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising α-aminoboronic acids and methods of use thereof.

Beta-lactamase inhibitors

Beta-lactamase inhibitors

Beta-lactamase inhibitors

Owner:NOVARTIS INT PHARM LTD

Methods for treating diabetes

InactiveUS20060063719A1Reducing blood glucoseLower blood sugar levelsBiocideDipeptide ingredientsPhysiologyType 2 diabetes

The invention relates to compositions of Glu-boroPro and methods of use thereof in the prevention or management of type 2 diabetes.

Methods for treating diabetes

Methods for treating diabetes

Methods for treating diabetes

Owner:POINT THERAPEUTICS

Boron-containing small molecules

ActiveUS7767657B2BiocideAntimycoticsBoron containingFungal nail infection

This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and / or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

Boron-containing small molecules

Boron-containing small molecules

Boron-containing small molecules

Owner:ANACOR PHARMACEUTICALS LLC

Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent

ActiveUS7514469B2BiocideNervous disorderDiseaseMedicine

The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—Free-B-ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions mediated by the COX-2 and 5-LO pathways. The present invention further provides a novel method for simultaneously inhibiting the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) enzymes, and reducing cox-2 mRNA production. Finally, the present invention includes a method for weight loss and blood glucose control. The methods of this invention are comprised of administering to a host in need thereof an effective amount of the composition of this invention together with a pharmaceutically acceptable carrier. This invention relates generally to the prevention and treatment of diseases and conditions mediated by the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) pathways, including but not limited to the relief joint discomfort and pain associated with conditions such as osteoarthritis, rheumatoid arthritis, and other injuries that result from overuse.

Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent

Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent

Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent

Owner:UNIGEN

Compounds for enzyme inhibition

InactiveUS20070105786A1Inhibiting and reducing HIV infectionAffecting levelBiocideNervous disorderEnzyme inhibitionAziridine

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles

Compounds for enzyme inhibition

Compounds for enzyme inhibition

Compounds for enzyme inhibition

Owner:ONYX THERAPEUTICS

Beta-lactamase inhibitors

InactiveUS20100120715A1Antibacterial agentsBiocideStereochemistryBeta-Lactamase Inhibitors

Disclosed herein are α-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising α-aminoboronic acids and methods of use thereof.

Beta-lactamase inhibitors

Beta-lactamase inhibitors

Beta-lactamase inhibitors

Owner:NOVARTIS INT PHARM LTD +1

Biaryl compounds as serine protease inhibitors

InactiveUS6699994B1Organic chemistryPeptide/protein ingredientsSerine Protease InhibitorsFactor VIIa

Compounds of formula (I) are useful as inhibitors of trypsin like serine protease enzymes such as thrombin, factor VIIa, factor Xa, TF/FVIIa, and trypsin. These compounds could be useful to treat and/or prevent clotting disorders, and as anticoagulating agents.

Biaryl compounds as serine protease inhibitors

Biaryl compounds as serine protease inhibitors

Biaryl compounds as serine protease inhibitors

Owner:BIOCRYST PHARM INC

Boron-based wood preservatives and treatment of wood with boron-based preservatives

InactiveUS20050013939A1Safe handlingConvenient treatmentBiocideBoron compound active ingredientsAlcoholPreservative

A process for treating wood comprising applying to the surface of the wood a boron based preservative which reacts with moisture within the wood to form a boron compound and alcohol and subjecting the wood with the applied preservative to a substantially moisture-free and enclosed environment for a period sufficient for the applied preservative to be absorbed into the wood and to produce the boron compound on reaction with the moisture in the wood and for the alcohol by-product of the reaction to be adsorbed within the wood structure.

Boron-based wood preservatives and treatment of wood with boron-based preservatives

Boron-based wood preservatives and treatment of wood with boron-based preservatives

Boron-based wood preservatives and treatment of wood with boron-based preservatives

Owner:UNIVERSITY OF MELBOURNE

Methods and compositions for treating proliferative diseases

ActiveUS20070116774A1Heavy metal active ingredientsBiocideNanoparticleCombination therapy

The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.

Methods and compositions for treating proliferative diseases

Methods and compositions for treating proliferative diseases

Methods and compositions for treating proliferative diseases

Owner:ABRAXIS BIOSCI LLC

Boron-containing small molecules as anti-inflammatory agents

ActiveUS8039450B2BiocideSenses disorderMedicineBoron

Compounds and methods of treating anti-inflammatory conditions are disclosed.

Boron-containing small molecules as anti-inflammatory agents

Boron-containing small molecules as anti-inflammatory agents

Boron-containing small molecules as anti-inflammatory agents

Owner:ANACOR PHARMA INC

Eponemycin and epoxomicin analogs and uses thereof

InactiveUS20050101781A1Useful in treatmentBiocidePeptide/protein ingredientsPharmaceutical drugOncology

The present invention provides compounds haviang formula (1): wherein R₁-R₆, A, J, D, E, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors.

Eponemycin and epoxomicin analogs and uses thereof

Eponemycin and epoxomicin analogs and uses thereof

Eponemycin and epoxomicin analogs and uses thereof

Owner:EISIA R&D MANAGEMENT CO LTD

Popular searches

Nanomedicine Animal repellants Macromolecular non-active ingredients Antineoplastic agents Nanocapsules Radioactive preparation carriers Carbohydrate active ingredients Amide active ingredients Respiratory disorder Dermatological disorder

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Try Eureka

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap